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Toward personalized synchrotron microbeam radiation therapy
Abstract
Synchrotron facilities produce ultra-high dose rate X-rays that can be used for selective cancer treatment
when combined with micron-sized beams. Synchrotron microbeam radiation therapy (MRT) has been
shown to inhibit cancer growth in small animals, whilst preserving healthy tissue function. However, the
underlying mechanisms that produce successful MRT outcomes are not well understood, either in vitro or
in vivo. This study provides new insights into the relationships between dosimetry, radiation transport
simulations, in vitro cell response, and pre-clinical brain cancer survival using intracerebral gliosarcoma
(9LGS) bearing rats. As part of this ground-breaking research, a new image-guided MRT technique was
implemented for accurate tumor targeting combined with a pioneering assessment of tumor dosecoverage; an essential parameter for clinical radiotherapy. Based on the results of our study, we can now
(for the first time) present clear and reproducible relationships between the in vitro cell response, tumor
dose-volume coverage and survival post MRT irradiation of an aggressive and radioresistant brain cancer
in a rodent model. Our innovative and interdisciplinary approach is illustrated by the results of the first
long-term MRT pre-clinical trial in Australia. Implementing personalized synchrotron MRT for brain cancer
treatment will advance this international research effort towards clinical trials.
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Toward personalized synchrotron
microbeam radiation therapy
Elette Engels 1,2, Nan Li1,2, Jeremy Davis1, Jason Paino1, Matthew Cameron1,
Andrew Dipuglia1, Sarah Vogel 1, Michael Valceski1, Abass Khochaiche1, Alice O’Keefe1,
Micah Barnes 3, Ashley Cullen1,4, Andrew Stevenson3, Susanna Guatelli1,2,
Anatoly Rosenfeld1,2, Michael Lerch1,2, Stéphanie Corde 1,2,5 & Moeava Tehei 1,2 ✉
Synchrotron facilities produce ultra-high dose rate X-rays that can be used for selective cancer
treatment when combined with micron-sized beams. Synchrotron microbeam radiation therapy
(MRT) has been shown to inhibit cancer growth in small animals, whilst preserving healthy tissue
function. However, the underlying mechanisms that produce successful MRT outcomes are not well
understood, either in vitro or in vivo. This study provides new insights into the relationships between
dosimetry, radiation transport simulations, in vitro cell response, and pre-clinical brain cancer survival
using intracerebral gliosarcoma (9LGS) bearing rats. As part of this ground-breaking research, a
new image-guided MRT technique was implemented for accurate tumor targeting combined with a
pioneering assessment of tumor dose-coverage; an essential parameter for clinical radiotherapy. Based
on the results of our study, we can now (for the first time) present clear and reproducible relationships
between the in vitro cell response, tumor dose-volume coverage and survival post MRT irradiation of
an aggressive and radioresistant brain cancer in a rodent model. Our innovative and interdisciplinary
approach is illustrated by the results of the first long-term MRT pre-clinical trial in Australia.
Implementing personalized synchrotron MRT for brain cancer treatment will advance this international
research effort towards clinical trials.
In the last 30 years, treatment outcomes for brain cancer in children and young adults have remained at a
stand-still. Despite significant progress in brain cancer treatment involving surgical resection, radiotherapy and
chemotherapeutics, the inherent resistance of these cancers challenge treatment success1. The prognosis is even
poorer for high-grade gliosarcomas and glioblastoma multiformes (GBMs), and treatments must balance the
risk of neurological deficits2. Consequently, there has been little improvement in brain and CNS cancer survival
between 1990 and 2016 (only −2.2% difference in mortality) despite a 17% increase in incidence3. Due to the
extremely invasive nature of high-grade brain cancers, treatments remain challenging and research into novel
therapies with improved outcomes are still needed.
Synchrotron microbeam radiation therapy (MRT) is an innovative cancer treatment technique proposed
in 19924. MRT implements spatially fractionated beams of kilovoltage radiation that are tens of microns in
width and spaced hundreds of micrometers apart. The synchrotron radiation source is extremely brilliant and
non-divergent, capable of producing a high-flux of photons leading to irradiation dose-rates upwards of thousands of Gray (Gy) per second5. The synchrotron microbeam array contains micron-sized beamlets that promote
radiosurgical treatment of cancers (with in-beam, or peak doses, of hundreds of Gray). Further, normal tissue
sparing is observed, due to the biologically tolerable dose between microbeams (defined as the valley dose).
Numerous pre-clinical studies support the reduction in normal tissue damage with MRT, while effectively treating the cancer5–8.
Amongst the synchrotron facilities that provide the technical pre-requisites to explore MRT, there is significant variation between treatment techniques including beam dimensions and spacing, beam filtration, image
guidance, dose rates and doses. A major uncertainty in prescribing MRT is relating these parameters to systematic
tumor control. Early studies4,9–12 use skin entrance doses as a standard, providing insufficient knowledge of the
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Mode
SBB

MRT

Mean
energy
(keV)

Beam height (mm); Intrinsic dose rate
(Gy/s) in Solid
Beam width (cm);
Number of columns Water

PVDR

Cu (1.41)
Al (2.82)

71.4

0.27;1; 4

40 at 24 mm

N/A

Figs. 4, 5
Table 2

3

Cu (1.41),
Cu (1.41)

95

0.49; 1; 4

205 at 24 mm

N/A

Fig. 4
Table 2

2

Cu (1.41)
Al (2.82)

71.4

0.27; 1; 4

40 (peak), 5 (valley)
at 24 mm

8.4 ± 1

Fig. 5

3

Cu (1.41)
Al (2.82)

81

0.5; 0.8; 1

350 (peak), 5 (valley)
at 5.5 mm

71 ± 2

Figs. 6–8

Wiggler
Field (T)

Filtration
(mm)

2

®

Result
Ref.

Table 1. Beam configurations for SBB and MRT, in vitro and in vivo at the Australian Synchrotron IMBL. All
intrinsic dose rates and beam geometry are measured at the sample position. PVDR uncertainty is evaluated
within 1 standard deviation. Result references are shown to relate the parameters used to experimental data.

tumor dose coverage at depth. A few recent studies6,12–15 describe the valley and peak dose in the brain at depth,
however, there is scarce individualized tumor volume coverage, as typically used in clinics. Image guidance in
MRT is necessary to ensure tumor coverage but is not implemented in all studies. Le Duc et al.16 is among the few
studies to consider co-registration of images and positioning animals accordingly to better target brain tumors.
Spatially fractionated MRT doses are challenging to compare with existing modalities. Studies such as Smyth et
al.17 have surmised that the MRT valley dose is the most relatable parameter to standard broad beam treatments,
yet the effect of the dose spatial modulation is not well understood.
Furthermore, direct relationships between in vitro and in vivo MRT studies are scarce. While in vitro studies
are performed to discern the response of cells to MRT18,19, they are not correlated directly to in vivo studies.
Ideally, as the current focus of clinical practice is personalization, patterns in in vitro studies should be used to
predict in vivo responses in an effort to personalize MRT for better patient specificity. MRT could also benefit
from more clinically oriented approaches to treatment planning. The MRT dose coverage of the tumor volume
and organs at risk (OAR) must be further investigated. This requires knowledge of the peak and valley dose distribution in the anatomy, and MRT related normal tissue toxicities.
Normal tissue responses to MRT show good tolerance to valley doses greater than 18 Gy5–7,10,20–24. However,
clinical signs in animals following MRT are not well documented. Brain tumor treatment in human patients can
cause adverse effects, including tiredness, skin reactions, headaches, nausea, seizures and hair loss22. Previous
pre-clinical MRT studies have few reports of early radiation symptoms, and there is no standard for symptom
management for brain MRT to-date. No long-term side effects are typically found however, in terms of cell functionality20, memory loss23, motor function and behavior24.
The future of MRT therefore requires the correlation of dosimetry and treatment planning, accurate imaging
of brain tumors and image guidance, and reporting of clinical signs and symptom management. To date, there
are no pre-clinical studies in MRT that combine the necessary dosimetry, image guidance, treatment planning
and short- and long-term follow-up. This study is designed to demonstrate the necessary steps for optimization of personalized pre-clinical MRT of high grade brain cancer: treatment planning, radiobiological insights,
image-guidance, and symptom management strategies.

Methods

Synchrotron radiation beam configuration and characterization. Irradiations were conducted
using the dynamic mode option at hutch 2B of the Imaging and Medical Beamline (IMBL) at the Australian
Synchrotron, 34.1 m from the source. The X-ray beam was produced via a 2–3.2 Tesla superconducting multipole
wiggler. Full details of beam configurations available at IMBL for synchrotron broad beam (SBB) and microbeams
are described by Stevenson et al.25. Microbeams were produced by passing the beam through a tungsten carbide
multi-slit collimator (MSC); 8 mm thick, 40 mm wide and 4 mm high. This produced microbeams (50 µm in
width and 400 µm pitch), as described in Stevenson et al.25. Due to the width of the intrinsic irradiation field size
used (10 mm at the sample position), in vitro experiments required irradiation of 12.5 cm2 flasks in four columns.
For in vivo experiments, a single column of unidirectional microbeams was used. The complete beam configuration parameters for cell and animal experiments are shown in Table 1, also found in Dipuglia et al.26.
In vitro experiments, dosimetry and treatment verification. The dosimetric protocol for SBB and
MRT at the IMBL is outlined in previous publications25–31. Briefly, it involves characterizing the pre-filtered SBB
uniform in custom designed RMI-457 Gammex Solid Water phantoms (Gammex-RMI, Middleton, WI, USA)
using a PinPoint ionization chamber (IC) (PTW 31014, Freiburg, Germany), calibrated to a traceable standard.
A micron-scale spatial resolution X-Tream dosimeter27,28 was then calibrated at the same reference conditions:
20 × 20 mm2 SBB field at a 20 mm depth. After the insertion of the MSC, the MRT field was characterized using
the X-Tream system at 20 mm depth. Microbeam peak and valley doses, and the Peak-to-Valley Dose Ratio
(PVDR) were measured for treatment planning. The valley was defined near-midway between microbeam peaks.
Final validation was performed with complementary radiation transport simulations before cell and pre-clinical
experiments.
Prior to every experiment, the final in vitro irradiation doses were verified at the same depth as the monolayer
of cells (24 mm) within a 15 × 15 × 15 cm3 Gammex solid water phantom30 with a 12.5 cm2 cell flask insert that
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Treatment

α (Gy−1)

β (Gy−2)

RER10

2T

0.124 ± 0.028

0.0162 ± 0.0042

1.27 ± 0.10

3T

0.740 ± 0.079

0.0371 ± 0.0212

4.07 ± 0.28

Conventional
150 kVp X-rays

0.112 ± 0.030

0.0088 ± 0.0035

1

Table 2. Comparison of all broad beam treatments with regard to radiobiological parameters α and β
(according to Eq. 1). The 2 T and 3 T treatment identifiers correspond to the different spectra and dose rate
conditions indicated in Table 1. Dose Rate enhancement ratio (RER10) values measured at 10% survival are
compared against the conventional 150 kVp X-ray treatment.

Figure 1. Geant4 Monte Carlo calculated 3 T (Cu/Al) microbeam dose profile (A) at the entrance (0.25 mm)
and tumor depths (5.5 mm) in water. MRT irradiation depth dose curve (B) showing the peak (red) and
valley (green) doses in water, overlaid with the micro-CT sagittal profile of a rat in this study to show the dose
distribution in the rat and tumor (location indicated by white arrow). Monte Carlo calculated peak and valley
doses were verified dosimetrically at 12.5 mm depth.

®

is used to perform the irradiation. For MRT, the X-Tream dosimeter, a PTW microdiamond31, and Gafchromic
EBT3 film (24 hour post irradiation analysis only) were used to verify the dose. For SBB, Gafchromic EBT3 film
and PinPoint IC were used to confirm doses. For each irradiation, a film was placed on the back-side (downstream) of the cell flask to confirm the irradiation geometry (SBB or MRT).

®

In vivo experiments dosimetry and treatment verification. After calibration of the X-Tream dosim-

®

eter in the reference conditions, the dose was measured in a 25 × 25 × 50 mm3 Solid Water phantom at 12.5 mm
depth for the reference field. The MRT treatment field was further collimated with an 8 × 8 mm2 conformal mask
and dosimetrically characterized by the X-Tream dosimeter at a 12.5 mm (reference) depth within the phantom.
The peak dose, valley dose and PVDR were measured horizontally across 5 central microbeams and associated
valley regions at a 5 and 10 μm sampling step size, respectively.
Experimental SBB IC measurements were compared with Geant4 radiation transport simulations modelling
the experimental set-up for quality assurance purposes27. The Geant4 simulation (version 9.6, patch 4, and using
the Livermore Polarized Physics List to model EM interactions) described by Dipuglia et al.26 was used to evaluate the MRT peak and valley doses at tumor depth. X-Tream measurements were made at a 12.5 mm reference
depth in the Solid Water phantom with precise quantification and tuning of the peak and valley dose using the
vertical motor translation speed. Geant4 simulations were then validated with experimental dose measurements
at 12.5 mm depth. The dose at tumor depth (5.5 mm) could then be calculated using the Monte Carlo simulation
and the vertical translation speed adjusted to deliver the prescribed treatment dose. In this experiment, the prescribed tumor valley dose was 15 Gy.
Figure 1A shows the microbeam lateral dose profile at the entrance and tumor depth, as simulated in Geant4.
The peak and valley doses with respect to a range of depths in water are shown in Fig. 1B. This information was
used to determine the MRT dose to the tumor and whole brain for a posteriori treatment planning purposes.

®
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Figure 2. Location of the smallest 9LGS tumor using micro-CT imaging 11 days after injection shown in the
red circle in transverse (left), coronal (middle) and sagittal (right) views. Burr hole location is shown (arrow).

Figure 3. CT anatomical images acquired day 11, and X-ray radiography alignment and MRT irradiation on
day 12. Day 11 micro-CT coronal reconstruction showing target outline (A), 3D volume rendering of bony
anatomy and alignment points (B), planar X-ray alignment (C), and MRT irradiation with film entry and exit
verification (D). Red box shows the 8 × 8 mm2 MRT delivery field and tumor position (cross) inside (not to
scale).

In vitro protocols. Cell preparation. 9 L gliosarcoma (9LGS) is a native gliosarcoma of Fischer rats which
contains glial components of glioblastoma multiforme and a sarcomatous component32. 9LGS cells were acquired
from the European Collection of Cell Cultures (ECACC). The cells were cultured in T75 cm2 flasks containing
complete Gibco Dulbecco’s modified eagle medium (c-DMEM), i.e. with 10% foetal bovine serum (FBS) and 1%
penicillin and streptomycin (PS). Cells were incubated at 37 oC and 5% (v/v) CO2. 9LGS cells were sub-cultured
into T12.5 cm2 flasks (BD FalconTM) containing c-DMEM prior to irradiation.

®

Cell irradiation. 9LGS cells were irradiated at room temperature using clinical orthovoltage or synchrotron
X-ray sources. Conventional broad beam (CBB) irradiation of 9LGS was performed at the Prince of Wales
Hospital (Randwick, NSW, Australia) using orthovoltage X-rays. T12.5 cm2 flasks containing monolayer of 9LGS
and 6 mm of c-DMEM were irradiated in horizontal position at a distance of 50 cm from the source in full scatter conditions including Solid Water below and adjacent to the cells. X-rays were generated using a Nucletron
Oldelft Therapax DXT 300 Series 3 Orthovoltage x-ray machine (Nucletron B.V., Veenendaal, The Netherlands).
The tube peak voltage was 150 kVp with a beam current of 20 mA, incident on a tungsten target and using downstream filtration of 3 mm Be and additional 0.35 mm of copper and 1.5 mm of aluminium (HVL = 0.68 mm Cu).
These X-rays were used to irradiate the cells with a dose rate of 0.76 Gy/min for doses ranging from 1– 8 Gy at
6 mm depth.
At the Australian Synchrotron, cells were irradiated upright in hutch 2B using the dynamic radiotherapy
modality at the IMBL for MRT and SBB modes, as given in Table 1. T12.5 cm2 flasks containing a monolayer of
9LGS were filled with Hank’s Balanced Salt Solution (HBSS), such that cells were located at 2.4 cm depth. Full
scatter conditions were created by using a Gammex Solid Water phantom material below and adjacent to the
flask of cells. Irradiation of flasks was delivered at a minimum scanning rate of 10 mm/s which delivered 1 Gy or
0.4 Gy in the valley to the cells for SBB and MRT, respectively. To cover the 12.5 cm2 area of the cells, the treatment
was divided into several columns, shown in Table 1. Dose verification was performed as described above.

®

®

Scientific Reports |

(2020) 10:8833 | https://doi.org/10.1038/s41598-020-65729-z

4

www.nature.com/scientificreports

www.nature.com/scientificreports/

Figure 4. Comparison of synchrotron radiation (with wiggler fields of 2 T and 3 T in Table 1) and conventional
orthovoltage radiation on 9LGS cell survival with respect to dose. Errors were determined from the standard
deviation of several experiments.

Figure 5. 9LGS cell survival using a 2 T wiggler field SBB and MRT (valley dose shown), compared to CBB
irradiation. Mean energy of X-rays is 66 keV. Errors were determined from the standard deviation of averages
measured over 2 separate experiments. A polynomial fit was applied to the MRT survival curve for visual
purpose.

Cell processing following irradiation. For clonogenic assays, cells were washed with DPBS and trypsinized before
seeding 3 triplicates at low density into 100 mm petri dishes with 10 mL of c-DMEM. After 15 doubling times,
each dish was washed with 5 mL DPBS (with Ca2+/Mg2+) and stained with a 1:3 (v/v) crystal violet solution
with 2.3% crystal violet stock (Sigma Aldrich ) and 70% ethanol. The surviving colonies of 50 cells or more
were counted and compared with the initial seeding number to determine the plating efficiency (PE). For each
group, the surviving fraction (SF) was calculated by taking the ratio of the PE of the irradiated cells, by the PE
of the non-irradiated control. Cell survival data was fitted using GraphPad Prism 7. MRT cell experiments were
repeated twice, broad beam 1–4 times. Errors and error bars were evaluated using one standard deviation from
the mean.

®

In vivo protocols.

All operative procedures and animal care were in conformity with the guidelines of
the Australian Code for the Care and Use of Animals for Scientific Purposes33 and under the approval of the
University of Wollongong and Australian Synchrotron animal ethics committees agreements (AE17/05 and
AS-2017-01).

Tumor implantation and animal monitoring.

A total of ten 7-week old inbred male F344/Arc (Fisher
344) rats from the Animal Resource Centre, Canning Vale, Perth, Australia were housed at the Australian
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Synchrotron, Clayton, Victoria, Australia in individually ventilated cages containing Pura chips bedding, specialty irradiated feed, access to water and environmental enrichments in groups of 2 or 3. Rats were sub-grouped
into MRT-treated or controls, with 5 animals per group.
All rats experienced 1 week of acclimation, before tumor implantation surgery at 8 weeks old. 2 hours prior
to surgery, pre-emptive analgesia was provided by voluntary oral administration of 0.4 mg/kg buprenorphine in
Nutella (Ferrero Australia Pty Ltd, Lithgow NSW, Australia). Prior to surgery, 9LGS cells were harvested from
T75cm3 flasks by washing with DPBS, and trypsinizing for 5 minutes. Cells were washed and suspended twice in
serum-free DMEM for injection.
Rats were inducted with 5% isoflurane in oxygen and general anesthesia (GA) was maintained with 2.5- 3%
isoflurane. Ophthalmic lubricant was applied to protect the eyes and each rat was placed on a heat mat, monitored
by PhysioSuite , (Kent Scientific Corporation, Torrington CT USA). Vital signs including respiratory rate, body
temperature and blood oxygen levels were monitored and maintained between 45–65 bpm, 37–38.5 oC, 95–100%,
respectively. This ensured all rats recovered from surgery without complications.
Once stable under GA, the scalp was shaved, and the rat was placed on a small animal Kopf Model 900 stereotaxic frame including microinjection unit (Kopf Instruments, Tujunga CA, USA). Bupivacaine was injected
subcutaneously in the scalp for local analgesia. A solution of 10% povidone iodine antiseptic was then applied to
the scalp and a disposable sterile plastic sheet covered the rat.
An aseptic environment was created to avoid complications post-surgery including sepsis34. Surgical drapes,
instruments, and equipment and protective gear were autoclaved before surgery, with surgical equipment sterilized for each rat35. A dorsal midline incision was made through the plastic sheet commencing posterior to the
eyes and extending rostral to the ears. The skull was exposed, and any minor bleeds cauterized. A 0.6–0.8 mm
burr hole was made at 3.5 mm to the right of the bregma crossing on the skull using a 1.4 mm K-wire.
The 9LGS cells at a concentration of 10,000 cells per µL were drawn into a 2 µL Neuros Hamilton syringe with
a 30-gauge needle (Hamilton Company, Reno NV, USA) and was loaded on the microinjection unit. The syringe
needle was inserted through the burr hole to a 6 mm depth into the caudate nucleus of the brain, over 2 minutes.
Before injection, the syringe was retracted 0.5 mm to produce a void for the cells. 1 µL of cells was injected with
the microinjection unit over 3 minutes. Before withdrawing the needle, cells were allowed to settle for 1 minute.
The needle was extracted over 3 minutes. After needle withdrawal, the burr hole was disinfected with alcohol and
the wound closed with polypropylene non-absorbable monofilament sutures.
Each rat was given fluid replacement subcutaneously prior to recovery and placed in a warmed recovery cage
individually. After 15–20 minutes, fully conscious and mobile rats were returned to their home cage. 12 hours
after surgery, another dose of buprenorphine was administered to maintain analgesia. Rats were monitored for
post-surgical complications twice daily for 3 days, then once daily for another 11 days.

®

Tumor imaging. All rats were prepared for CT imaging using a Siemens Inveon PET/CT Scanner at the
Monash Biomedical Imaging (MBI) Facility, Clayton, Victoria, Australia on day 11 post-tumor injection. Prior
to imaging, the rats were pre-warmed under a heat lamp before anaesthesia induction using 5% isoflurane. The
rats were maintained at 2.5–3% isoflurane for CT imaging, and warmed with a heat mat. Vital signs monitored
and maintained.
An iodine contrast agent, Iomeron-350 (Regional Health Care Group, Rosebery, NSW & Bracco Ltd), was
used to visualize the tumor against the normal brain tissue. Before iodine injection, the tail was warmed to dilate
veins in the tail. The tail was disinfected with water and 70% (v/v) ethanol before a 24 G ¾” Teflon catheter was
inserted into the lateral tail vein. 1 mL of iodine was gradually injected (an initial 0.3 mL bolus over 10 s, and the
remaining 0.7 mL over 4 minutes) using a pump for imaging during the 8 minute CT acquisition. Rats were positioned on small couch bed with ear bars to keep the skull level in the field. CT was acquired at 80 kVp energy and
200 ms exposure in a 8.7 cm by 8.7 cm field-of-view. Final pixel size was 97 µm. Rats were given oxygen to recover
from anaesthesia following imaging, and warmed in isolation, before returning to their home cage.
The tumor positions were determined with respect to the bony anatomy of the rat. The position of a tumor
at day 11 in coronal, horizontal and sagittal views inside the head is shown in Fig. 2 for the rat containing the
smallest tumor (surviving rat).
MRT. On day 12, 5 rats received MRT in hutch 2B on IMBL with each rat receiving 15 Gy in the valley at the
target depth of 5.5 mm. 5 rats remain untreated for survival and behavioral comparison. Prior or after MRT, rats
willingly ingested 1.5 mg/kg meloxicam as a preventative measure for inflammation following MRT.
After induction with 5% isoflurane, rats were maintained under general anaesthesia at 2.5–3% isoflurane while
warmed with heat mats and heat lamp. Vital signs including respiratory rate and temperature were monitored as
previous. Rats were mounted on the Kopf stereotaxic frame without the microinjection unit using a bite block and
ear bars. The frame was secured on the treatment stage, securing the rat vertically, with the beam directed through
the top of the skull (Fig. 3D). A heat lamp was used for warming during the treatment.
Individual tumors were aligned in the MRT field using an image guidance method developed for pre-clinical
radiotherapy applications on IMBL36 and the CT image. The IMBL image guidance system (SyncMRT)36, was
adapted to allow isocentric tumor positioning in the MRT array. 2 planar X-rays of each rat were taken prior
to MRT, using an X-ray tube and detected on a Hamamatsu flat panel detector. The total imaging dose of the
micro-CT scan and the planar X-ray to the skin was 8.91 ± 0.24 cGy (as determined using a MOSkinTM detector37).
The X-ray images were then co-registered with the CT image of bony landmarks obtained using the Inveon
PET/CT. Landmarks for co-registration between the CT image and the X-ray image were verified within
±0.1 mm, between the anterior and posterior orbits of the eyes, across the bregma line and the length of the skull.
Once the X-ray image was aligned with the CT image, the tumor position was targeted by the alignment system.
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The stage holding the Kopf stereotaxic frame was rotated and translated in 4 degrees of freedom accordingly for
each rat to ensure tumor coverage in the 8 × 8 mm2 field. This unidirectional field is equivalent to the planning
treatment volume (PTV), and fully contains the gross tumor volume (GTV). Figure 3 summarizes the alignment
procedure.
Once the image alignment was performed, the rat was treated with MRT. Immediately prior to treatment, 2
pieces of Gafchromic film were placed anterior and posterior to the tumor position, to verify the MRT irradiation delivery location. The single fraction, unidirectional, MRT delivery was performed using 3 T, 81 keV mean
energy X-ray microbeams according to Table 1. Tumor dose coverage was achieved by moving the target (and
mask) vertically at a rate of 0.5 mm/s, translating the 0.5 mm high intrinsic MRT field in the cranial to caudal
direction on each rat. With this speed, the prescribed dose of 15 Gy in the valley was delivered at the tumor depth,
shown in Fig. 1.
As part of the ethically approved animal management plan during the investigation, diazepam was given
(4 mg/kg) by intra-peritoneal injection following MRT and after recovery to prevent over-stimulation of rats in
recovery.
Rats were monitored for the effects of tumor growth twice daily up to day 200, after which monitoring frequency was changed to once daily. Weight changes, neurological signs, gait, mobility, porphyrin staining, surgical
site inflammation, and signs of discomfort were scored. In accordance with humane endpoints defined in the
ethics approval, animals were euthanized if scoring exceeded normal values in these categories, or scored cumulatively in neurological signs, gait, mobility surgical site inflammation and weight categories. Death was not used
as an endpoint in any part of this project.

®

Tissue processing.

After euthanasia (following the scoring of clinical signs), the brain of each rat was
removed by opening the top of the skull and placed immediately in 10% neutral buffered formalin for immersion
fixation. Fixed brains were sliced transversely, processed routinely through graded alcohols and xylene, embedded in paraffin, and 4 µm sections stained with haematoxylin and eosin. Histology images were acquired using 4x
magnification on a Nikon Eclipse TS100 microscope with a Teledyne Lumenera Infinity2 (5 MP USB digital
color) microscope camera.

®

®

Retrospective treatment planning with MRT. For the first time, treatment planning has been implemented to describe the long-term survival outcomes following MRT irradiation of 9LGS. Combining all information from the simulation, dosimetry, imaging, and in vitro studies, the first patient-specific MRT treatment
planning was performed for brain cancer.
CT images of each rat were processed through MATLAB 38 to distinguish tumor margins and determine
the volume of each tumor as it varies with depth. The 8 × 8 mm2 microbeam field entirely covered the tumor in
each rat, such that any variation dose coverage occurred only with depth from the surface of the skin. In this way,
tumor dose was evaluated for each rat using the predicted Monte Carlo dose, and verified with dose calculations
as 12.5 mm depth in Solid Water only. For this study, cortical bone and realistic rat geometry was not included.
Combining this information with the CT derived tumor volume distribution, dose-volume histograms (DVHs)
of each tumor were obtained. The whole brain volume (excluding the gross tumor volume) was also considered
as an organ at risk (OAR).

®

®

Results

Cell response to broad synchrotron radiation.

First, the effect of synchrotron radiation on 9LGS cells
in vitro was compared to conventional orthovoltage X-rays. The major difference between the conventional kilovoltage and synchrotron therapies is the rate at which dose is delivered, as mean energies are comparable (see
Table 1). Figure 4 compares the SBB treatments, detailed in Table 1, with the conventional 150 kVp orthovoltage
X-rays.
For the same dose range, the impact of increasing the dose rate was synonymous with an increase in 9LGS
cell death. The dose rates at the level of the cells using synchrotron 2 T and 3 T wiggler strengths are 40 Gy/s
and 205 Gy/s, respectively, compared to the 0.76 Gy/min used with conventional X-rays. Only at a dose rate of
205 Gy/s are significant cell lethality differences noted between the conventional treatment. Cellular dose rate
dependence is also seen with FLASH radiotherapy39, in favor of normal tissue protection and with equivalent
tumor responses. However, our result indicates a greater dose rate influence on the 9LGS cell line, that could
produce not only better normal tissue sparing, but radiosensitization of the tumor.
Table 2 summarizes the radiobiological parameters. The most significant change to the radiobiological parameters is the change in the linear component, α. Ranging from 0.124 to 0.740 Gy−1, the greatest factor in the change
to α is the dose rate of the radiation treatment. The RER10 is largest for the high dose rate 3 T treatments due to the
dose rate response of the cells and the increase in β also.

Cell response to synchrotron microbeam radiation therapy. Figure 5 compares the cell survival of
9LGS using CBB, SBB, or MRT using a 2 T wiggler field. MRT produces more cell death than CBB or SBB when
evaluating the cell survival against the valley dose. This is due to the increased lethality produced by the peak
dose. The change in shape of the cell survival trend does not appear to be linear quadratic when including low
doses. The gradient of the survival curve changes and is a function of the individual peak and valley population
survivals. At high doses, the cell survival curve tends to follow the trend of the low dose rate SBB or CBB survival
of 9LGS, offset by the population of cells that are abolished in the peak.
Overall MRT causes greater reduction in cell survival compared to SBB for the 2 T low dose rate result (Fig. 5).
Ideally, for the treatment of 9LGS, a higher dose rate in the valley is required to replicate the important drop in cell
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Figure 6. Fischer rat survival post 9LGS implantation for non-irradiated and MRT treated rats with 3 T MRT
(see Table 1).
survival seen with the 3 T SBB in Fig. 4. Based on these results, the pre-clinical study was optimized in the next
section using a 3 T wiggler field, as shown in Table 1.

Pre-clinical 9LGS Treatment. MRT was performed according to Table 1, with 15 Gy in the valley at the
center of the tumor centered in the beam. MRT caused short-term and temporary symptomatic radiation-induced
edema in 3 rats, which presented as seizing. Some seizing symptoms were present up 4.5 days after MRT, with the
majority of symptoms noticed 2 hours – 1 day after MRT. Meloxicam and diazepam were used for the remaining
rats to reduce the risk of seizure activity.
The survival of all rats treated with MRT compared to the non-irradiated group is shown in Fig. 6. MRT
treated rats showed significantly longer survival than non-irradiated rats. The mean survival time (MST) and
median survival time (MeST) with non-irradiated rats was found to be 20 and 21 days, respectively. In comparison the MST and MeST for rats treated with 3 T Cu/Al, using 15 Gy in the valley, was 135 and 44 days,
respectively. The increase in lifespan (ILS) due to the MST and MeST is therefore 570% and 110%, respectively.
These results represent the first long-term animal survival study at the Australian Synchrotron. No long-term
adverse effects were observed following MRT, and there was no noticeable decline in cognition, vision, mobility, or behavior in treated rats. These observations were made longitudinally twice daily by the same observers.
Informal observations were made of rat behavior and ability to learn and remember skills for food rewards (see
Supplementary Video). We observed no significant changes to personality or social behavior and were able to
remember commands and develop new skills for food before and after MRT. Rat behavior was seen to change
only when brain cancer reoccurred.
Histological analysis of the brain was performed to observe the effect of microbeams on the brain and tumor
tissue with respect to time. Figure 7 shows the 9LGS tumor and surrounding normal tissue over time, as stained
with H&E.
The histological appearance of the 9LGS tumor in untreated rats was consistent with that in published descriptions20,39. Tumors were not encapsulated with locally invasive margins (Fig. 7E–G) and were composed of pleomorphic, occasionally multinucleate spindle cells with a moderate number of mitotic figures. 1 day after MRT
(day 13), H&E staining showed dark tumor cells in reoccurring tracks, corresponding to microbeam peak spacing
of 400 μm (Fig. 7F). With time and persistent tumor growth, (Fig. 7G), microbeam tracks were no longer present
due to repopulation of tumor cells. On closer inspection, cells resembling lymphocytes were detected 1–4 weeks
after MRT infiltrating the tumor (Fig. 7G) with some focal edema. In the case of complete recovery and tumor
ablation (Fig. 7H), some scar tissue was observed in the region with a large supporting vasculature structure.
In the normal brain, no microbeam tracks were distinguishable using H&E staining 1 day after MRT on day
13 (Fig. 7F), however there was evidence of perivascular vacuolation, indicative of edema. By day 32 (Fig. 7B),
microbeam tracks became visible in the normal brain. Between microbeam tracks, normal tissue was indistinguishable from normal untreated brain, highlighting the tissue sparing effect of MRT. Over time (Fig. 7C,D),
microbeam tracks become fainter and distorted in normal tissue. At day 60, one rat had small mineralizations
(orange in color in Fig. 7C) present throughout the tissue. In the cured rat (day 528), fewer microbeam tracks
were seen in the brain. Figure 7D shows some of the more distinguishable microbeam tracks found. Very little
mineralization was present and some vacuoles or necrosis were seen where microbeam tracks existed.
Despite deficits in cells along microbeam tracks, no pathologic features were observed in between the
microbeams, and the animals did not experience a decline in cognition or signs of abnormal behavior throughout
their lives. Cancerous tissue clearance was seen to be aided by heightened immune activity 1–4 weeks after MRT
in the form of accumulating lymphocytes within the tumor, which plays a key role in cancer elimination, and
has been reported elsewhere6. Some features such as collapsed vasculature (Fig. 7C) was noted, and also seen by
Barbone et al. We did observe some calcification in tissue after 1 year, however, Barbone et al. observed significantly more 1.5 months after MRT, perhaps due the larger 9LGS size at the time of treatment (treated day 15).
Retrospective MRT treatment planning.

To understand the factors contributing to successful MRT
outcomes, a homogenous treatment planning approach was adopted using the CT data of each rat to determine
the tumor volume distribution with respect to depth. This is a first approximation of patient-specific treatment
planning for MRT using CT imaging, in vitro results, and Monte Carlo dose coverage. The results are shown in
Fig. 8 for rats surviving 32, 44, 60, and 528 days after tumor implantation.
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Figure 7. Rat brain histology using H & E staining. The 9LGs tumor was located in the caudate putamen/
striatum. The normal tissue was compared in the striatum and cortex. Normal tissue in untreated rat, day 20
(A), and MRT treated rats at day 32 (B), day 60 (C), and day 528 (D) after tumor implantation. Untreated tumor
at day 20 (E), is compared to MRT treated tumors at days 13 (F), and 44 (G). Complete tumor ablation, leaving
only scar tissue, day 528 (H). Microbeam tracks indicated with arrows, tumor supporting vasculature (*), tissue
vacuolation (+) 1 day after MRT.

Using the volume distribution in Fig. 8A, a dose volume histogram (DVH) was generated for each rat. The
dose coverage of individual tumor volumes were computed using the experimentally validated Monte Carlo peak
and valley doses. Furthermore, the dose with depth to the brain OAR, was assessed. Figure 8B shows the results
for each of the rats in Fig. 8A, including the dose coverage to the brain OAR. Using the tumor DVH, there is a
correlation between the tumor-dose coverage and survival in Fig. 8. The best coverage of the tumor volume with
15 Gy resulted in the complete survival case.
Table 3 reviews the tumor coverage shown in the Fig. 8 and evaluates the equivalent uniform dose (EUD).
EUD was derived in each case according to Eq. 1, using the simple EUD (Gy) calculation method outlined by
Niemierko40.
 N
1
EUD (Gy) = Dref ln  ∑vi ⋅ SF8Gy
 N i =1

(

Di

)D

ref


 /ln SF
8Gy



(1)

Over each partial tumor volume or voxel, vi, up to a total number of voxels, N, the corresponding dose, Di, is
related to a reference dose, Dref, chosen from the in vitro MRT data at 8 Gy with corresponding survival (SF8Gy).
This reference dose was chosen, rather than the previously used 2 Gy reference40, to avoid using the in vitro data
that includes viable cells in the microbeam peak (as described in section Cell response to synchrotron microbeam
radiation therapy). 8 Gy is also the minimum valley dose tumor voxels may receive.
While tumor volume was related to the treatment success, the overall survival was related to dose coverage.
The tumor coverage varied between each rat due to the differences in tumor volumes with depth. As a result, the
proportion of each tumor that received 15 Gy varied. This was seen to have consequences for survival when examining the remaining physical volume of 9LGS tumor that received less than 15 Gy. The likelihood for tumor recurrence increased proportionally with the tumor volume not covered by the 15 Gy isodose curve. Other parameters
including the dose to 90% of the tumor showed that 14.7 Gy produced the most successful survival outcomes. In
reviewing the DVH data, the most important factors in survival appear to be the tumor volume receiving 15 Gy
rather than the total tumor volume or the dose to 90% of the tumor volume.
For the OAR, 21% of the whole brain received 8 Gy, with 12% of the whole brain receiving less than 15 Gy.
2.8% of the brain received the peak dose of 800–1000 Gy.

Discussion

In this study, we developed a new framework for reporting and designing future MRT procedures for brain cancers, which, due to inherent radioresistance, require more rigorous and novel treatment strategies. The in vitro
irradiation of 9LGS predetermined the tumor response before treating in vivo, similar to personalized medicine
studies41,42. Typically, predicting radio-curability involves analysis of biopsies43, or potential biomarkers42,44–46.
The response of 9LGS towards specific treatments such as MRT or broad beam in our study offered a means
of clarifying certain trends in tumor sensitivity to radiation directly before in vivo treatment. Conventional
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Figure 8. 9LGS tumor volume distribution with respect to physical depth from the surface of the skin (A) was
measured from microCT images (top-left) and used to develop MRT dose volume histograms (B) for the gross
tumor volumes (GTV) of rats surviving 32 days, 44 days, 60 days, and 528 days compared to the whole brain
(OAR). CT datasets were thresholded for the tumor using MATLAB 2018. Limits in accuracy are produced
due to the finite pixel size of 97 µm by 97 µm. Monte Carlo evaluated MRT dose with depth was verified
dosimetrically at 12.5 mm as described in the Methods.

Rat
Survival
(days)

Tumor
Volume
(mm3)

Tumor Volume
Receiving 15 Gy (%)

Tumor Volume Receiving
less than 15 Gy (mm3)

Dose to 90%
Volume (Gy)

EUD
(Gy)

32

8.42

53.58

3.91

14.4

15.3

44

1.38

26.02

1.02

13.2

14.6

60

1.72

44.57

0.95

14.7

15.3

528

0.59

72.22

0.16

14.7

15.4

Table 3. Summary of rat survival after tumor implantation and other contributing factors including tumor
volume, the tumor volume receiving 15 Gy, dose to 90% of the tumor volume and the EUD evaluated using cell
survival parameters.

kilovoltage radiotherapy of 9LGS (shown previously47), identified the significant radioresistance of cells at clinical
dose rates (in order of <1 Gy/min). Synchrotron radiation was superior to conventional X-rays in the treatment
of 9LGS if delivered at a dose rate of 205 Gy/s. This expands on previous findings48, showing that the 9LGS can be
radiosensitized using synchrotron high dose rate fields, similar to FLASH therapies39.
MRT irradiations of 50 µm microbeams spaced at 400 µm peak-to-peak. Previous studies suggest that MRT
survival can be correlated to broad beam conditions using the valley dose9, and this approach was adopted for
this study. However, the cell survival curves showed two distinct trends of dose-effect relationships, depending
on the MRT valley dose. MRT irradiation with a valley dose greater than 3 Gy exhibits a similar trend to SBB; only
cells in the valley region are viable, with cells in the peak receiving lethal radiation doses. For valley doses lower
than 3 Gy, however, cells within microbeam peaks are viable, further decreasing the overall cell survival compared
to SBB for doses <3 Gy. Thus, this dose range is where MRT could be most beneficial compared to broad beam,
either as a stand-alone treatment or in combination with other normal tissue sparing strategies. These could
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include clinical dose fractionation schemes or experimental dose enhancement techniques (such as nanoparticle
radiosensitization).
The broad beam dose rate of 205 Gy/s could not be achieved in the valley, due to the beam collimation for
MRT. However, this must be considered in the future, to benefit from both FLASH and the radiosurgical properties of MRT. A possible method of implementing this may be through cross-fired or interlaced MRT49, but this is
at the expense of greater normal tissue exposure. Without dose rate dependence, MRT increased 9LGS cell death
compared to lower dose rate broad beam irradiations, SBB (40 Gy/s) and CBB (0.76 Gy/min), due to the radiosurgery of the microbeam peaks.
The in vivo MRT results followed the expectations of the in vitro experiments and were a product of rigorous
dosimetry and tumor alignment with the MRT field.
With a MST of 135 days and MeST of 44 days, we have superior survival to the cross-fired treatment of Le
Duc et al.10 and Regnard et al.17,50, and some of the unidirectional treatments of Dilmanian et al.16. However, it
is difficult to directly compare between studies due to differing dose rates, beam geometry, tumor volume51 and
unknown dose coverage of the tumor. The result from Regnard et al.17 predicts a 12.6 Gy valley dose at tumor
depth and has a similar MeST of 40 days to our study, but with less overall survival.
By guaranteeing treatment accuracy and considering patient health, the survival outcomes reflect the expectations of tumor dose coverage of 15 Gy for 9LGS cells and long-term quality of life. The normal tissue sparing and
radiosurgery of MRT was verified using histology results (Fig. 7). The microbeams caused an early response in
the tumor 24 hrs after MRT, leading to immune-mediated clearance of 9LGS debris 2–4 weeks later. The normal
tissue instead recovered over time, to show little difference between untreated and treated brain tissue. Only faint
microbeam tracks remain in the brain 72 weeks after MRT. Moreover, MRT made no significant impact on rodent
weight gain and growth, or had any noticeable behavioral effects. The 9LGS tumor was cured in 1 rat (which has
been rehomed after no cancer was detected 1 year later).
There were, however, differences in the survival that could be a result of disparities in tumor size and location.
The previous approach of using a dose of 15 Gy at 5.5 mm depth has been adopted in other studies6,10,16, but is not
synonymous with treatment success. By considering true dose coverage, using CT imaging and dosimetrically
verified Monte Carlo MRT doses, the first individualized treatment planning in MRT for 9LGS was retrospectively performed to understand links between rodent survival and tumor dose-volume coverage. While tumor
size was a factor, tumor ablation was ensured if 72% of the tumor volume received 15 Gy, with an EUD of 15.4 Gy.
Future studies must include treatment planning before MRT, to assess adequate tumor coverage, and further minimize normal brain (OAR) doses. To remedy the variations in dose with depth, a bolus may be used to increase
the depth for shallow tumors. By performing treatment planning and adjustments to tumor depth for each rat
prior to treatment, MRT outcomes can be largely improved.
Whilst the survival outcomes were promising in this study, short-term complications occurred, such as temporary symptomatic radiation-induced cerebral edema after MRT. Other treatments have not reported these
short-term symptoms, including MRT performed at the European Synchrotron Research Facility (ESRF) using
18 Gy in the valley. What is shown in previous studies such as Fardone et al.24, is that MRT does not have long
term effects on the sensorimotor cortex. The temporary symptoms seen in our investigation therefore may be due
to the larger field size or lower dose rate used on the IMBL compared to in vivo studies at the ESRF, which may, as
a result, produce different normal tissue tolerances. It was further postulated that the use of isoflurane anaesthesia, rather than ketamine-based anaesthesia used in other MRT studies10,15, causes more inflammation. Isoflurane
provides better recovery but produces higher heart rates and blood pressure compared to ketamine52. Isoflurane
may also increase the blood oxygen supply to the tumor, hence, the improvement in radiation treatment in vivo53.
The initial inflammation may be reduced if the symptoms can be managed correctly, as no lasting effects in this
study were seen with the use of Diazepam and Meloxicam. Anti-inflammatory strategies will be investigated further in future MRT studies at IMBL, to determine management techniques.

Conclusion

This study provides the first long term MRT animal survival study at the Australian Synchrotron. It identifies the
key mechanisms involved in understanding the treatment outcomes of MRT as a brain cancer treatment modality.
Thanks to ‘personalized’ in vitro cell modelling, pre-clinical MRT was optimized. Using state-of-the-art advanced
dosimetry, Monte Carlo, and image guidance, precise in vitro and in vivo MRT was performed.
Histology results supported the survival data and indicated the stages in tumor control, or repopulation, after
MRT, including normal tissue recovery. For the first time, recommendations for analgesia and sedation were
reported, to allow for better recovery and symptom management. Individualized treatment planning for brain
cancer MRT was implemented to find tumor coverage and other factors contributing to optimum MRT outcomes.
In this study, 8-week-old 9 LGS rats were treated with MRT. Without long-term side effects, this adolescent
rat model has promising outcomes for treatment for children with brain cancer, which is often associated with
high risks to quality of life. This study highlights the key advantages and strategies for improved brain cancer
MRT using a small animal model. Normal tissue sparing, radiosurgical tumor control, and exceptional long-term
quality of life were achieved. These developments are the first steps towards personalized clinical strategies using
MRT. The extension of this work to larger animals is required, but may ultimately improve the outcome for young
patients with brain cancer.
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